Gout Treatment and Clinical Considerations: The Role of Pegloticase, Colchicine, and Febuxostat

被引:3
|
作者
Quintana, Michael J. [1 ]
Shum, Alika Z. [1 ]
Folse, Michael S. [1 ]
Ramesh, Prerana C. [2 ]
Ahmadzadeh, Shahab [3 ]
Varrassi, Giustino [4 ]
Shekoohi, Sahar [3 ]
Kaye, Alan D. [3 ]
机构
[1] Louisiana State Univ, Hlth Sci Ctr, Sch Med, Shreveport, LA USA
[2] Louisiana State Univ, Hlth Sci Ctr, Radiol, Shreveport, LA USA
[3] Louisiana State Univ, Hlth Sci Ctr, Anesthesiol, Shreveport, LA 71103 USA
[4] Paolo Procacci Fdn, Pain Med, Rome, Italy
关键词
uric acid; gout; krystexxa (pegloticase); colcrys (colchicine); uloric (febuxostat); INDUCED HEMOLYTIC-ANEMIA; INHIBITOR; HYPERURICEMIA; SAFETY; PHARMACODYNAMICS; PHARMACOKINETICS; MULTICENTER; MANAGEMENT;
D O I
10.7759/cureus.46649
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Gout treatment has evolved rapidly in recent decades, and various drugs have been designed for acute and chronic management. Three medications used to treat gout include pegloticase, colchicine, and febuxostat. When prescribing these drugs, important factors to consider include pharmacokinetics, pharmacodynamics, population specifics, benefits, and contraindications. Pharmacokinetic considerations of each drug include absorption, distribution, metabolism, and elimination factors. Pharmacodynamics factors are assessed by their potential for toxicity and effects on serum uric acid levels. Additionally, the drug's targeted population must be considered to avoid unwanted complications in certain pre-existing conditions such as cardiovascular disease or glucose-6-dehydrogenase (G6PD) deficiency. In this paper, we aim to provide insight into the gout medications, pegloticase, colchicine, and febuxostat. This review will include their pharmacokinetics, pharmacodynamics, population specifics, benefits, and contraindications.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Pegloticase in gout treatment - safety issues, latest evidence and clinical considerations
    Guttmann, Allison
    Krasnokutsky, Svetlana
    Pillinger, Michael H.
    Berhanu, Adey
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2017, 8 (12) : 379 - 388
  • [2] Clinical and Health Care Use Characteristics of Patients Newly Starting Allopurinol, Febuxostat, and Colchicine for the Treatment of Gout
    Kim, Seoyoung C.
    Schmidt, Bernhard M. W.
    Franklin, Jessica M.
    Liu, Jun
    Solomon, Daniel H.
    Schneeweiss, Sebastian
    ARTHRITIS CARE & RESEARCH, 2013, 65 (12) : 2008 - 2014
  • [3] The role of febuxostat in gout
    Bardin, Thomas
    Richette, Pascal
    CURRENT OPINION IN RHEUMATOLOGY, 2019, 31 (02) : 152 - 158
  • [4] Febuxostat for the treatment of gout
    Bridgeman, Mary Barna
    Chavez, Benjamin
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (03) : 395 - 398
  • [5] Clinical characteristics of juvenile gout and treatment response to febuxostat
    Zheng, Shaoling
    Lee, Pui Y.
    Huang, Yukai
    Deng, Weiming
    Huang, Zhixiang
    Huang, Qidang
    Chen, Shuyang
    Li, Tianwang
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (04) : 599 - 600
  • [6] Pegloticase (Krystexxa) for Treatment of Refractory Gout
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2011, 53 (1357): : 9 - 10
  • [7] Febuxostat for treatment of chronic gout
    Gray, Charnelda L.
    Walters-Smith, Nafesa E.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2011, 68 (05) : 389 - 398
  • [8] Febuxostat - Treatment for hyperuricemia and gout?
    Moreland, LW
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (23): : 2505 - 2507
  • [9] Febuxostat for the treatment of hyperuricaemia in gout
    Robinson, Philip C.
    Dalbeth, Nicola
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (11) : 1289 - 1299
  • [10] Clinical and Health Care Use Characteristics of Patients Newly Prescribed Allopurinol, Febuxostat and Colchicine for Gout
    Kim, Seoyoung C.
    Schmidt, Bernhard M. W.
    Liu, Jun
    Solomon, Daniel H.
    Schneeweiss, Sebastian
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 55 - 55